Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Joseph Yazdi

Neurological Surgery Saint Louis, MO Medical Doctor

NPI 1972500981 CMS profile 44325

1034 S Brentwood Blvd Ste 754, Saint Louis, MO 63117

Open in the dashboard

General payments

$1,875

42 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Joseph Yazdi of Saint Louis, MO is reported in the CMS Open Payments database as having received $1,875 across 42 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 41st percentile of Neurological Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $15 1
2023 General $34 2
2022 General $82 1
2020 General $1,439 10
2019 General $306 28

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Joseph Yazdi
  • Neurological Surgery median
  • Middle half of Neurological Surgery
  • National median

In program year 2025, general payments to Joseph Yazdi were reported at $0. Among 5,467 Neurological Surgery profiles paid that year, the median was $596 and the middle half received between $159 and $3,102.

Show as a table
Year Joseph Yazdi Neurological Surgery median Middle half National median
2019 $306 $582 $138–$3,006 $163
2020 $1,439 $294 $76–$2,174 $114
2021 $0 $387 $105–$2,432 $132
2022 $82 $542 $139–$2,989 $149
2023 $34 $534 $145–$2,697 $160
2024 $15 $574 $155–$3,046 $164
2025 $0 $596 $159–$3,102 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. Medtronic USA, Inc. $1,479 12 payments
  2. Zyla Life Sciences $172 22 payments
  3. Medtronic, Inc. $82 1 payment
  4. Boston Scientific Corporation $33 2 payments
  5. Caerus Corp. $30 1 payment
  6. SI-BONE, Inc. $25 1 payment
  7. Stimwave Technologies Incorporated $22 1 payment
  8. Abbott Laboratories $16 1 payment
  9. AbbVie, Inc. $15 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Travel and Lodging $1,187 2 payments
  2. Food and Beverage $688 40 payments
Products named General payments · program years 2019–2024
  1. PIVOX Oblique Lateral Spinal System Tl $1,316 5 payments
  2. SPRIX $164 21 payments
  3. RESTORE $113 4 payments
  4. PIVOX Oblique Lateral Spinal System Tl $82 1 payment
  5. PRESTIGE $40 2 payments
  6. WaveWriter Alpha Prime 16 $33 2 payments
  7. IFUSE IMPLANT $25 1 payment
  8. Proclaim Family of SCS IPGs $16 1 payment
  9. QULIPTA $15 1 payment
  10. CD HORIZON $10 1 payment
  11. Other $8 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 11 drugs

Part D claims

251

Median for Neurosurgery: 83

Drug cost

$2,500

Median for Neurosurgery: $872

Branded share of claims

15.1%

Median for Neurosurgery: 16.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 38 $862
Gabapentin Generic 44 $553
Tramadol Hcl Generic 31 $339
Tizanidine Hcl Generic 22 $181
Meclizine Hcl Generic 13 $180
Ropinirole Hcl Generic 12 $114
Dexamethasone Generic 25 $93
Diclofenac Sodium Generic 14 $78
Escitalopram Oxalate Generic 29 $57
Alprazolam Generic 11 $31

The 10 drugs with the highest cost, of 11 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,779 Part D prescribers listed as Neurosurgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 18 billing codes

Paid by Medicare

$7,694

Medicare's payments for the services billed

Medicare patients

21

Average age 68

Services billed

70

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

42 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurological Surgery in Missouri

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record